[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Akiva Mintz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":137},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,74,100,118],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100614822",false,"NCT07284589","Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting SSTR2 Radiotracer Uptake","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions: SSTR targeted therapies\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",true,"ALL","18 Years","120 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours",[27,28,29],"Healthy (Controls)","Healthy Volunteers","Neuroendocrine (NE) Tumors",[31,32,33,34,35,36,37],"PET","PET\u002FCT","SSTR2","neuroendocrine","dotatate","low dose","nuclear imaging","RECRUITING","2026-04-07",{"date":41,"type":42},"2026-04-08","ACTUAL",{"date":44,"type":42},"2025-12-11",{"date":46,"type":21},"2030-04-30",{"name":48,"class":49},"Akiva Mintz","OTHER",1,{"id":52,"slug":4,"hasResults":10,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100593942","NCT07012993","Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol","Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake","Inclusion Criteria:\n\nAge ≥18 years; Ability to provide informed consent and comply with study procedures; For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\nParticipants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total); More than four prior enrollments in this study; Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan; Pregnant or breastfeeding individuals (negative pregnancy test required); Inability to provide informed consent; Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours",[61,62,63,28],"Alzheimer Disease","Mild Cognitive Impairment","Dementia",[65,31,66,32],"Amyloid","ultralow dose",{"date":68,"type":42},"2026-04-13",{"date":70,"type":42},"2025-05-20",{"date":72,"type":21},"2030-06-30",{"name":48,"class":49},{"id":75,"slug":4,"hasResults":10,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":99},"100614820","NCT07284563","Ultralow Dose PET Imaging for 18F-NaF Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting 18F-NaF Uptake","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions\n* Concurrent treatments that may interfere with radiotracer uptake as determined by the Principle Investigator.\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.",[84,85,86,87,88],"Healthy Volunteer","Bone Alteration","Bone and Joint Cancer","Bone and Joint Infection","Arthritis",[31,32,36,37,90,91],"sodium fluoride","bone","2025-12-08",{"date":94,"type":42},"2025-12-16",{"date":96,"type":42},"2025-09-01",{"date":72,"type":21},{"name":48,"class":49},2,{"id":101,"slug":4,"hasResults":10,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":50},"100589590","NCT06956391","Ultralow Dose PET Imaging of 18F-FDG Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting 18F-FDG Uptake","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Ability to provide informed consent and comply with study procedures.\n3. For female participants:\n\n   * Must not be pregnant or breastfeeding.\n   * Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).\n2. More than four prior enrollments in this study.\n3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n4. Medication \\& Prior Treatment Exclusions\n5. Pregnant or breastfeeding individuals (negative pregnancy test required)\n6. Inability to provide informed consent\n7. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.",[84,110],"Cancer","2025-06-01",{"date":113,"type":42},"2025-06-04",{"date":115,"type":42},"2025-05-12",{"date":72,"type":21},{"name":48,"class":49},{"id":119,"slug":4,"hasResults":10,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":136,"locationsCount":50},"100585588","NCT06904313","Ultralow Dose PET Imaging for PSMA Expression","Evaluation of Ultralow Dose PET Imaging for Detecting PSMA Expression","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Ability to provide informed consent and comply with study procedures.\n3. For female participants:\n\n   * Must not be pregnant or breastfeeding.\n   * Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).\n2. More than four prior enrollments in this study.\n3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n4. Medication \\& Prior Treatment Exclusions\n\n   • Concurrent PSMA-targeted therapy (e.g., lutetium-177).\n5. Pregnant or breastfeeding individuals (negative pregnancy test required)\n6. Inability to provide informed consent\n7. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard?\n\nParticipants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours",[84,128],"Prostate CA",[130,131,132,37],"PET scan","prostate cancer","psma",{"date":113,"type":42},{"date":115,"type":42},{"date":72,"type":21},{"name":48,"class":49},""]